A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of Evolocumab (AMG145) on LDL-C in Subjects With Severe Familial Hypercholesterolemia.
Phase of Trial: Phase II/III
Latest Information Update: 17 Jul 2018
At a glance
- Drugs Evolocumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Adverse reactions; Registrational
- Acronyms PROFICIO; TAUSSIG
- Sponsors Amgen
- 29 May 2018 Status changed from active, no longer recruiting to completed.
- 30 Aug 2017 Results (n=14) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
- 21 Aug 2017 According to an Amgen media release, data feom this trial will be presented at the European Society of Cardiology (ESC) Congress 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History